

IPR & Innovation**Boehringer Ingelheim and Sutter Health Establish Research Collaboration to Improve Patient Care, [Pharma Focus Asia](#)**

RIDGEFIELD, Conn., and SACRAMENTO, Calif., May 11, 2015 /PRNewswire/ -- Boehringer Ingelheim, a family-owned biopharmaceutical company, and Sutter Health, a not-for-profit health system in Northern California, today announced the start of a five-year research and health care innovation collaboration, which will explore and test the value of digital health solutions, mobile technologies, and insights from advanced data analytics in the delivery of health care.

Johnson & Johnson Expands IP Policy to Create Broad Access in 128 Countries for Development of New a, [The Telegraph](#)

- Expanded Policy will Increase Access for Darunavir Pediatric Formulations in 128 Resource-Limited Countries RARITAN, New Jersey , May 11, 2015 /PRNewswire/ -- Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have furthered their commitment to improve the health of children living with HIV through an expanded policy aimed at enhancing access to its HIV medicine darunavir .

Patent office rejects J&J arm's plea for HIV drug intermediate, [Financial Express](#)

In a setback to US consumer health behemoth Johnson & Johnson, India's patent office has rejected an application... In a setback to US consumer health behemoth Johnson & Johnson, India's patent office has rejected an application from Janssen Pharmaceutica NV, the company's pharma arm, for an intermediate of Rilpivirine, an HIV drug. The patent office's order came in response to a pre-grant opposition filed by Indian pharma company Cipla against the grant of patent.

Calcivis Announces Headline Results of Clinical Study, [The Telegraph](#)

EDINBURGH , May 11, 2015 /PRNewswire/ -- Primary Performance End Point Met in First Study of Calcivis® Caries Activity Imaging System Calcivis, a medical devices company focused on revolutionising the management of tooth decay and enabling preventive dentistry, today announces headline results from the first clinical study of its Calcivis® Caries Activity Imaging System. The study met its primary performance endpoint relating to the System's ability to identify early active caries lesions and an excellent safety profile was observed.

Cyclenium Pharma, Haplogen sign drug discovery pact, [Pharmabiz.com](#)

Cyclenium Pharma Inc., an emerging pharmaceutical company specialising in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen GmbH, a biotechnology company developing anti-infective drugs, have signed a research pact aimed at the discovery of novel pharmaceutical candidates in multiple disease areas. The collaboration brings together two next generation drug discovery platforms: Cyclenium's CMRT Technology-derived QUEST Library and associated hit-to-lead optimisation expertise with Haplogen's unique haploid genetics technology and expertise in host target identification, validation and screening.

Immense scope for nano-science and technology in drug researches: Dr V Rajendran, [Pharmabiz.com](#)

There is immense scope for nano-science and nano-technology in drug researches which impacts highly on diagnostics and drug delivery in modern days. The research and development (R&D) in

the area brings good results for the pharmaceutical industry in terms of personalized drugs production in place of blockbuster drug models, according to Dr V Rajendran, director of the Centre for nano-science and technology at KSR Group of Institutions at Namakkal in Tamil Nadu. According to him, nano-science and technology is a new approach in pharmaceutical sector. Nano medicine, nano biomaterials and nano biotechnology contribute much to the modern medicine to counter various diseases.

India's First Nicotine Patch, 2baconil™ Launched by Rusan Healthcare, [Financial Express](#)

India's first fully indigenous nicotine patch 2baconil™ was recently launched by Rusan Healthcare Pvt Ltd, a marketing arm of ... India's first fully indigenous nicotine patch 2baconil™ was recently launched by Rusan Healthcare Pvt Ltd, a marketing arm of the parent company Rusan Pharma Ltd, which is a global pharmaceutical company with interests in R&D, Manufacturing and Marketing of formulations, APIs and their intermediates.

Patent office rejects J&J arm's plea for HIV drug intermediate, [Financial Express](#)

In a setback to US consumer health behemoth Johnson & Johnson, India's patent office has rejected an application... In a setback to US consumer health behemoth Johnson & Johnson, India's patent office has rejected an application from Janssen Pharmaceutica NV, the company's pharma arm, for an intermediate of Rilpivirine, an HIV drug. The patent office's order came in response to a pre-grant opposition filed by Indian pharma company Cipla against the grant of patent.

Updated St. Gallen International Breast Cancer Guidelines reconfirm Oncotype DX® as the only multi-, [The Telegraph](#)

GENEVA , May 11, 2015 /PRNewswire/ -- Genomic Health today announced that the 14th St. Gallen International Breast Cancer Conference Expert Panel, for the third time, recognised the Onco type DX ® breast cancer test for its ability to provide not only prognostic but also predictive information regarding the likelihood of chemotherapy benefit for patients with early-stage, endocrine sensitive, invasive breast cancer. The Onco type DX test was the only multi-gene test accepted with a strong majority of panelists supporting it as a predictive tool.

UNC-Chapel Hill and GSK announce novel partnership to accelerate search for HIV cure, [Pharma Focus Asia](#)

CHAPEL HILL, N.C., May 10, 2015 /PRNewswire-USNewswire/ -- The University of North Carolina at Chapel Hill, a leading global public research university with significant expertise in HIV basic and clinical research, and GSK, a global, research-based pharmaceutical and healthcare company with a legacy of success in developing treatments for HIV, today announced the creation of the dedicated HIV Cure center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS.

Access to Healthcare

Govt to provide free diagnostic tests for all, [The Times of India](#)

NEW DELHI: The Centre is set to announce a scheme for providing free diagnostic tests, including several blood tests, x-rays and advanced CT scans, for those visiting public health facilities. Private service providers will be roped in wherever required. While the idea of providing free diagnostics has been hailed by all those aware of it, health economists and public health experts expressed concern over outsourcing the tests to the private sector, arguing that it is an "expensive and inefficient" way to provide the services.

Shipping containers turn hi-tech clinics for rural health delivery, [The Indian Express](#)

About 100 cloud connected micro health centres to be set up in country, one in Pune village on May

14. Written by Anuradha Mascarenhas | Pune | Modifying shipping containers into mobile clinics, equipped with lab investigation and telecommunications facilities, is the latest effort in disaster management. The aim is to set up more than 100 micro health centres across the country and one at Pabal village in Shirur tehsil of Pune district will be installed on May 14.

Strengthening India's healthcare system, [Yahoo! India](#)

By Amit Kapoor | IANS India Private Limited/Yahoo India News 7 minutes ago One of the biggest challenges India faces and will continue to face in the forthcoming decades is in the context of healthcare. It would include issues like health accessibility, infant mortality rates, the stunted growth of children because of ill health, maternal health, disease patterns among its adult population as well as the challenges pertaining to its ageing population, among others. It is bound to be further accentuated by processes like urbanization and ever-growing pollution levels.

Medical & Regulatory

'Generic drugs to be available at rates fixed by state govt', [Business Standard](#)

Essential and generic drugs will be available in Punjab only at rates fixed by the government, state Health Minister Surjit Kumar Jayani today said. Jayani directed drug inspectors and chemists to ensure the availability of essential and generic drugs only at the rates fixed by the government, an official spokesman said here. Issuing fresh guidelines to the drug inspectors, the Minister said that various steps have been taken by the Punjab government to improve health services and to check the ever increasing prices of the generic medicines.

Similar report appeared in

[Hindustan Times](#)

Risk, sold over the counter, [Bangalore Mirror](#)

An e-commerce company selling contraceptive pills and Viagra-type pills online has created quite a bit of a stir. The Food and Drugs Administration commissioner has clarified that this contravened the Drugs and Cosmetics Act for which a 3- to 5-year jail sentence and a minimum fine of Rs 100,000 is the prescribed punishment. Another drug available on the internet is melatonin, a natural chemical secreted in the body. I have seen this drug being sold over the counter for jet lag syndrome at major airports in the world.

Similar report appeared in

[Mumbai Mirror](#)

Get registered, NPPA tells pharma firms, [The Tribune](#)

Ambika Sharma Tribune News Service Solan, May 11 With top 59 of the 100 pharmaceutical companies failing to seek registration under the Integrated Pharmaceutical Database Management System (IPDMS), the National Pharmaceutical Pricing Authority has directed the companies to complete the procedure or face action. The authority had earlier fixed October 30, 2014, as the last date for making online registration under the new system and all companies were provided a user ID and a password.

AbbVie to Present New Data from Studies of Five Oncology Pipeline Assets in Multiple Cancers at the, [The Telegraph](#)

17 abstracts include data from:- Phase 1 trials evaluating venetoclax in relapsed or refractory multiple myeloma- Phase 2 study evaluating the potential of veliparib in advanced NSCLC patients with history of smoking- Studies of ABT-414 in glioblastoma multiforme and solid tumors, duvelisib in treatment naive chronic lymphocytic leukemia and elotuzumab in multiple myeloma NORTH CHICAGO, Illinois, May 11, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced 17 abstracts from studies of the company's oncology pipeline are being presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 - June 2, in Chicago.

Chiasma Announces New Data for Investigational Octreotide Capsules to be Presented at ECE 2015, [The Telegraph](#)

- Studies show acromegaly patients face significant burdens with available treatment options
NEWTON, Massachusetts and JERUSALEM , May 11, 2015 /PRNewswire/ --Chiasma, Inc., a U.S. privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced that two abstracts evaluating patients with acromegaly will be presented at the 17th European Congress of Endocrinology (ECE), being held in Dublin, Ireland , from May 16-20, 2015 .Photo - <http://photos.prnewswire.com/prnh/20150508/214830LOGO>"The data presented at this meeting add to the growing body of evidence suggesting a new treatment option is needed for people with acromegaly," said Mark Leuchtenberger , chief executive officer of

Similar reports have appeared in:

[Pharma Focus Asia](#)

Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism, [The Telegraph](#)

RYE, New York , May 11, 2015 /PRNewswire/ -- Curemark LLC, a privately held drug research and development company, announced the start of a new Phase III double blind, randomized, placebo-controlled clinical trial to examine the effect of its novel formulation, CM-AT, on all children ages 3-8 with Autism. Previously, Curemark announced the successful results of its FDA Phase III double blinded clinical trial for CM-AT in children ages 3-8 with Autism who had low levels of the digestive enzyme chymotrypsin.

Similar reports have appeared in:

[Pharma Focus Asia](#)

EMA Releases Draft Opinion on Two Patient-Reported Outcome (PRO) Measures for Evaluating New Treatme, [The Telegraph](#)

BETHESDA, Maryland , May 11, 2015 /PRNewswire/ -- Evidera , a leading provider of evidence-based solutions for the healthcare industry, is pleased to announce the release of the European Medicines Agency's (EMA) draft qualification opinion on the EXACT (Exacerbations of Chronic Pulmonary Tool) and E-RS (EXACT-Respiratory Symptoms), two patient-reported outcome (PRO) measures for evaluating treatment outcomes in COPD trials. The daily symptom diary that forms the basis for these instruments was developed as part of the EXACT-PRO Initiative , a multi-year, multi-sponsor project initiated and led by Evidera.

Govt assures to review track & trace on issues raised by industry, [Chronicle Pharmabiz - National](#)

To dispel the fears of the exporters over the impending track and trace system, the commerce ministry gave a sympathetic hearing to issues and concerns raised by the industry in a meeting held this week in Delhi. The ministry assured all the stakeholders that they would duly consider: take up the matter with the higher ups. Pharmaceuticals Export Promotion Council of India (Pharmexcil) had been closely working with the stakeholders to highlight and bring into the notice of the department problems relating to certain provisions in the track and trace system Following the

GW kicks off Phase III trial of cannabinoid in rare epilepsy, [PharmaTimes](#)

GW Pharmaceuticals has kicked off a Phase III clinical trial of its cannabinoid Epidiolex for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. Although there are approved treatments available for patients with LGS, "this severe form of epilepsy often remains particularly difficult to treat," says Justin Gover, GW's chief executive, adding "we believe that Epidiolex has the potential to meet this significant unmet need".

IPA asks to hold recovery of MACP in Andaman & Nicobar, [Chronicle Pharmabiz - National](#)

The Indian Pharmacists Association (IPA) on behalf of pharmacists in Andaman and Nicobar demands to hold the recovery of payment under Modified Assured Career Progression (MACP) scheme, as the matter is sub judice and pending in Delhi High Court. With the recent formation of new state branch in Andaman and Nicobar, IPA delegates met Dr Shipra Paul, director, Directorate of Health Services (DHS), Andaman and Nicobar to discuss the issue.

Inhaler ban boosts costs for people with asthma, [Yahoo! India](#)

(Reuters Health) - A 2008 ban on chlorofluorocarbons (CFCs) has ended up being particularly costly for people with asthma. The ban changed the type of albuterol inhaler available in the U.S., and since then costs have gone up and inhaler use has gone down, according to a new study. Albuterol inhalers prevent and treat wheezing, shortness of breath, coughing, and chest tightness due to asthma or chronic obstructive pulmonary disease. Generic albuterol inhalers using CFCs were banned and were replaced by more expensive inhalers using hydrofluoroalkane (HFA).

Metropolis Healthcare reports 21.8% tested positive for ovarian cancer in last two years, [Pharmabiz.com](#)

Ovarian cancer has emerged as one of the most common cancer affecting women in India. An analysis of samples collected over the past two years (2013-2014) by Metropolis Healthcare Ltd reveals that a total of 7945 tested positive for high CA125 levels out of the 36,515 samples processed at Metropolis Healthcare in Mumbai. According to Indian Journal of Cancer, 1 out of 5 women are prone to ovarian cancer. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary 9 out of 10 ovarian cancers are epithelial ovarian cancers.

Roche to present data from lung, blood cancer medicines at ASCO meeting, [Pharmabiz.com](#)

Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) annual meeting from May 29- June 2 in Chicago, United States. These data demonstrate the strength of Roche's oncology pipeline, particularly in cancer immunotherapy and personalised medicine. "We're particularly excited about our data in different types of advanced lung cancer, including pivotal data for alectinib and results of the first randomised study of our investigational immunotherapy, MPDL3280A," said Sandra Horning, M.D., Roche's

Therapeutic Goods Administration approves Akynzeo to prevent CINV, [Pharmabiz.com](#)

Specialised Therapeutics Australia (STA), an Australian biopharmaceutical company and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration (TGA) has approved Akynzeo for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy. Akynzeo is the first approved fixed dose combination oral agent that targets two critical signalling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule for the prevention of CINV."

Two-drug combination reduces colon cancer by 67 percent, [Yahoo! India](#)

By Indo Asian News Service | IANS India Private Limited/Yahoo India News " 11 minutes ago Barcelona, May 11 (IANS/EFE) An international phase one clinical trial published on Monday and led by Barcelona's Vall d'Hebron Hospital shows that a combination of two new antibodies, that act against the same protein, reduces by 67 percent tumours in colorectal metastatic cancers that no longer respond to conventional treatment. Josep Tabernero, head of Medical Oncology at Vall

d'Hebron Hospital and director of the Vall d'Hebron Oncology Institute, said "this is important progress because we have showed this improvement for the first time in a clinical

Similar reports have appeared in:

[Business Standard](#)

[Zee News](#)

US FDA approves Bayer HealthCare's Avelox to treat patients with plague, [Pharmabiz.com](#)

The US Food and Drug Administration (FDA) approved Avelox (moxifloxacin) to treat patients with plague, a rare and potentially fatal bacterial infection. The agency approval for plague includes use of the drug for the treatment of pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood). Avelox is also approved for prevention of plague in adult patients. Avelox is manufactured by Whippany, New Jersey-based Bayer HealthCare Pharmaceuticals. Plague is extremely rare in most parts of the world, including the United States, with 1,000 to 2,000 cases worldwide each year. The three most common forms of plague are bubonic plague

US FDA approves Nevro's Senza spinal cord stimulation system, [Pharmabiz.com](#)

Nevro Corp., a medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, has received approval from the United States Food and Drug Administration (FDA) for its Senza spinal cord stimulation (SCS) system. The Senza SCS system, which delivers Nevro's proprietary HF10 therapy, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain. The Senza system delivering HF10 therapy has experienced strong adoption in Europe and Australia over the past 5 years.

U.S. says insurers must cover FDA-approved birth control methods, [Yahoo! India](#)

(Reuters) - The U.S. government said health insurers must cover all FDA-approved methods of birth control without co-pays or charges to the patient, as it issued a paper on Monday looking to clarify coverage guidelines under the Affordable Care Act. Recent published reports found that some payers were ignoring federal requirements for covering birth control, a benefit under the healthcare reform commonly referred to as "Obamacare." On Monday, the Department of Health and Human Services issued a series of responses aimed at correcting misperceptions or potential coverage loopholes being exploited by some insurers.

ViaCyte to Present at Cavendish Global Health Impact Forum, [Pharma Focus Asia](#)

SAN DIEGO, May 11, 2015 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced two presentations at the upcoming healthcare event, the Cavendish Global Health Impact Forum. Dr. Paul Laikind, President and Chief Executive Officer, will give a company presentation and participate in a panel discussion hosted by CONNECT, a not-for-profit organization designed to catalyze the creation of innovative technology and life sciences companies in San Diego County.

Others

CPhI's 3rd Annual Pharma Project Management Conference to be held in Mumbai, [Express Pharma](#)

To focus on addressing challenges faced by project managers while handling projects in complex environment CPhI will conduct its 3rd Annual Pharma Project Management Conference, from June 29-30, 2015 at The Westin in Mumbai. The conference is focused on addressing challenges faced by project managers while handling projects in complex environment and gaining practical insights on quality and timely delivery of projects.

Debiotech Gets Option to Acquire Exclusive Rights From iSense for the Use of its CGM With Patch Pump, [The Telegraph](#)

LAUSANNE , Switzerland and WILSONVILLE, Oregon , May 11, 2015 /PRNewswire/ --Debiotech of Switzerland and iSense CGM, Inc. of the US, announced today having entered into an Agreement under which Debiotech has the option to acquire the exclusive rights on the iSense CGM product and technology for use with patch pumps for diabetes therapy. Financial terms and conditions of the Agreement are not disclosed. With close to 390 million people in the world having diabetes today (a number predicted to grow to around 592 million by 2035) and numerous studies showing the interest of combining accurate insulin delivery and Continuous Glucose

NHRC asks Union govt. to check misuse of banned drug, [The Hindu](#)

The National Human Rights Commission has asked the Union Ministry of Health and Family Welfare to constitute a committee for monitoring illegal use of banned drug, Diclofenac, in animals, which has deadly impact on vulture population in the country. The NHRC has issued the direction while hearing a complaint filed by Akhand, an Odisha-based human rights activist, who a year ago had alleged that Diclofenac poisoning has drastically brought down vulture population in India, pushing them to the brink of extinction. "Sudden drop in vulture population led to collapse of the natural animal disposal system in India that has had obvious and

Endo Acquires Broad Portfolio of Branded and Generic Products, Expanding International Pharmaceutica, [The Telegraph](#)

- Acquisition expected to be accretive in 2015, supports continued growth in South Africa and adds approximately 60 on-market products and nearly 70 R&D pipeline programs DUBLIN , May 11, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the acquisition of a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings, a leading publicly-traded South African company that supplies branded and generic products in more than 150 countries.

HighPoint Solutions, LLC and Entimo Announce Key Partnership, [The Telegraph](#)

EAST NORRITON, Pennsylvania , May 11, 2015 /PRNewswire/ -- HighPoint Solutions, LLC, a premier management consulting and specialized IT consulting firm for the pharmaceutical and medical device industries, announced today that they will be entering a strategic partnership with trusted provider, Entimo. Entimo, a highly specialized, product-focused software company, offers an integrated clinical environment (entimICE) ?? a truly metadata-driven, configurable and regulatory compliant solution platform for life sciences.

Hyderabad to host global pharma summit in July, [The Hindu](#)

Hyderabad will play host to a four-day global pharma expo and summit from July 23. With "Innovation and Advances"™ as its theme, the event will deliberate on a range of issues, from pharmaceutical technology to education, indigenous drugs and drug regulatory affairs, besides serving as a platform for joint ventures and project collaboration. Renowned pharmaceutical experts will be addressing the Indo-Global Pharma Expo and Summit 2015, being organised by Indus Foundation, in association with FTAPCCI and OMICS group, according to S.B. Anumolu, president of the Foundation.

iPHEX 2015 to commence from May 13 in Mumbai, [Pharmabiz.com](#)

Promoted by The Pharmaceuticals Exports Promotion Council of India (Pharmexcil), the third edition of iPHEX 2015 will be held at Bombay Exhibition Centre from May 13 to 15, 2015. iPHEX 2015 is India's own pharmaceutical show under the support of Ministry of Commerce & Industry, Department of Commerce, and Government of India. The exhibition will bring together the

drugs, pharmaceutical and healthcare industry, all under one roof. Pharmexcil will organise the exhibition and Ministry of Commerce and Industry, Department of Commerce, Government of India will support it.

Indian pharma cos lure Japan with generics contract manufacturing offer, [Business Standard](#)

After several failed efforts to tap the highly-lucrative, yet tough-to-crack generics market in Japan, the second-biggest pharmaceutical market in the world, the Indian pharma industry has now come up with a new offer -- contract manufacturing of Japanese generics in India. Japan remains a tough market for Indian drug manufacturers. Stringent regulations have made the Japanese market averse to buying Indian generics. Their understanding of the Indian pharma sector is not as good as that of the US or Europe, said P V Appaji, director-general of Pharmaceuticals Export Promotion Council of India (Pharmexcil), an initiative of the ministry of commerce and

Mycoplasma Testing Market Worth \$613.49 Million by 2019, [The Telegraph](#)

DALLAS , May 11, 2015 /PRNewswire/ --According to a new market research report " Mycoplasma Testing Market by Products (Instruments, Kits & Reagents, Services), Application (Cell Line, Virus, End of Production Cells), Technology (PCR, ELISA, Direct Assay), End User (Cell Banks, Pharmaceutical Companies) - Global Forecast to 2019 ", published by MarketsandMarkets, the global Mycoplasma Testing Market is expected to reach \$613.49 Million by 2019 from \$340.29 Million in 2014, growing at a CAGR of 12.51% between 2014 and 2019. Browse 74 market data Tables and 103 Figures spread through 175 Pages and in-depth TOC on " Mycoplasma

MEDITE Cancer Diagnostics, Inc. Reports 2014 Year End Results along with Expectations for 2015, [Pharma Focus Asia](#)

ORLANDO, Fla., May 11, 2015 /PRNewswire/ -- MEDITE Cancer Diagnostics, Inc., (MDIT) specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces 2014 results and expectations for 2015. In 2014, MEDITE Enterprise, Inc., with its subsidiaries in Germany , Austria and Poland , transformed through its purchase by CytoCore, Inc. from a privately owned company into a public company with a well know brand, 76 employees and an existing distribution network into about 70 countries. MEDITE is now recognized as an up and coming competitor in

Neusoft Medical Systems introduces NeuViz 128 CT for global markets, [Pharmabiz.com](#)

Neusoft Medical Systems Co., Ltd., a Chinese-based leading manufacturer of medical equipment and service, officially launched the NeuViz 128 CT for the global markets, and the new products are being exported to South Asia, North Africa and other international markets. Neusoft Medical Systems' CE certified NeuViz 128 CT combines the leading-edge technologies and innovations to create super-fine and low dose images, which can provide more accurate diagnostic information.

President Pranab Mukherjee to present Florence Nightingale Awards tomorrow, [The Economic Times](#)

NEW DELHI: President Pranab Mukherjee will present the National Florence Nightingale Awards to 35 nursing professionals on The Health Ministry had instituted the awards in 1973 as a mark of recognition for the meritorious services of nurses. "President Pranab Mukherjee will present the National Florence Nightingale Awards to nursing personnel tomorrow at Rashtrapati Bhavan on the occasion of International Nurses Day," an official statement said. JP Nadda as well as Minister of State for Health Shripad Yesso Naik will also be present on the occasion. "Until 2014 a total of 306 nurses were decorated with this award.